China Resources Pharmaceutical Group Limited provided earnings guidance for the six months ended 30 June 2022. Based on preliminary estimate, the total operating income of the company for the six months ended 30 June 2022 is expected to increase by approximately 48% year-on-year, and the net profit attributable to shareholders of the company is expected to increase by approximately 26% year-on-year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.78 HKD | -0.17% | -5.71% | +12.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.67% | 465.15Cr | |
+40.73% | 74TCr | |
+31.80% | 60TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+14.88% | 24TCr | |
+9.36% | 21TCr | |
-5.03% | 21TCr | |
+6.17% | 16TCr |
- Stock Market
- Equities
- 3320 Stock
- News China Resources Pharmaceutical Group Limited
- China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022